SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brady R, Kanfer JON, Shapiro D 1965 Metabolism of glucocerebrosides: Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J Biol Chem 240: 3942.
  • 2
    Beutler E, Grabowski GA 2001 Gaucher disease. In: ScriverCR, BeaudetAL, SlyWS, ValleD, ChildsB, KinzlerKW, VogelsteinB (eds). The Metabolic and Molecular Basis of Inherited Disease, 8th ed. McGraw-Hill, New York, NY, USA, 36353668.
  • 3
    Zevin S, Abrahamov A, Hadas-Halpern I, Kannai R, Levy-Lahad E, Horowitz M, Zimran A 1993 Adult-type Gaucher disease in children: Genetics, clinical features and enzyme replacement therapy. Q J Med 86: 565573.
  • 4
    Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, Wappner RS, Wisch JS, Weinreb NJ 1996 Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129: 149153.
  • 5
    Johnson LA, Hoppel BE, Gerard EL, Miller SP, Doppelt SH, Zirzow GC, Rosenthal DI, Dambrosia JM, Hill SC, Brady RO 1992 Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182: 451455.
  • 6
    Pastores GM, Einhorn TA 1995 Skeletal complications of Gaucher disease: Pathophysiology, evaluation, and treatment. Sem Hematol 32(Suppl 1): 2027.
  • 7
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE 1991 Replacement therapy for inherited enzyme deficiency: Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 14641470.
  • 8
    University of Washington 2006 Bone strength. Available at http://courses.washington.edu/bonephys/phystrength.html. Accessed February 22, 2006.
  • 9
    Pastores GM, Wallenstein S, Desnick RJ, Luckey MM 1996 Bone density in type 1 Gaucher disease. J Bone Miner Res 11: 18011807.
  • 10
    Lanir A, Hadar H, Cohen I, Benmair J, Schreiber R 1986 Gaucher disease: Assessment with MR imaging. Radiology 161: 239244.
  • 11
    Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JTR, Erikson A, Giraldo P, Goldblatt J, Hollak C, Ida H, Kaplan P, Kolodny EH, Mistry P, Pastores GM, Pires R, Prakash-Cheng A, Rosenbloom BE, Scott RC, Sobreira E, Tylki-Szymanska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A 2004 Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Sem Hematol 41: 1522.
  • 12
    Grabowski GA, Leslie N, Wenstrup RJ 1998 Enzyme therapy in Gaucher disease: The first five years. Blood Rev 12: 115133.
  • 13
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott R, Wappner R, Zimran A 2002 Effectiveness of enzyme replacement therapy in 1,028 patients with Type 1 Gaucher disease after 2–5 years of treatment: A report from the Gaucher Registry. Am J Med 113: 112119.
  • 14
    Rosenthal DI, Scott JA, Barranger J, Mankin HJ, Saini S, Brady TJ, Osier LK, Doppelt S 1986 Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 68: 802808.
  • 15
    Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, Elstein D 2004 Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 22: 597601.
  • 16
    Ciana G, Addobbah R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B 2005 Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28: 723732.
  • 17
    Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, Sun S 2004 Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104: 12531257.
  • 18
    Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A 2000 The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 28352843.
  • 19
    Hui SL, Gao S, Zhou X, Johnston CC Jr, Lu Y, Gluer CC, Grampp S, Genant H 1997 Universal standardization of bone mineral density measurements: A method with optimal properties for calibration among several instruments. J Bone Miner Res 12: 14631470.
  • 20
    Laird NM, Ware JH 1982 Random effects models for longitudinal data: An overview of recent results. Biometrics 38: 963974.
  • 21
    Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ 2002 Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(Suppl 1): A25A36.
  • 22
    Barton NW, Brady RO 1994 Gaucher disease: Skeletal responses to enzyme replacement therapy. Gaucher Clin Perspect 2: 811.
  • 23
    Pastores GM 1994 Gaucher disease type 1: Clinical assessment of bony disease. Gaucher Clin Perspect 2: 57.
  • 24
    Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC, Miller SPF, Brady RO, Barton NW 1995 Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629637.
  • 25
    Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144152.
  • 26
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 14371443.
  • 27
    Fleisch HA 1997 Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29: 5562.
  • 28
    Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH III 1997 Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103: 468476.
  • 29
    Maerevoet M, Martin C, Duck L 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99102.
  • 30
    Department of Health and Human Services, Centers for Disease Control and Prevention. BMI—body mass index: About BMI for adults. Available at http://www.cdc.gov/nccdphp/dnpa/bmi/adult_BMI/about_adult_BMI.htm. Accessed September 11, 2006.